Board of directors
Chairman of the Board
Christian Jourquin has devoted 42 years of his professional career to the Solvay Group, including 17 years as a member of the Executive Committee. From 1971, he was attached to the National Finance Department for Italy in Milan. Climbing the ladder one by one, he took over the management of a Dutch subsidiary in 1980, was appointed managing director for Spain and Portugal in 1990 and became managing director of the Chemical Sector in 2000. He joined the Board of Administration in 2005 and was appointed President of the Executive Committee in 2006 until May 2012 but also President of the European Council of the Chemical Industry and of the International Council of the Chemical Associations (2008 - 2010).
Chief Executive Officer
Enrico Bastianelli is the founder of TheraVet. Medical Doctor by training and holder of an MBA, Enrico Bastianelli acquired his business experience at McKinsey & Co. After creating several biotech companies, he founded and led Bone Therapeutics (a human bone cell therapy company) for 10 years. During this period, he took up many challenges such as the company's IPO (2015). He has 20 years of experience in biotech and medtech management.
Lotfi Yelles Chaouche
Lotfi Yelles Chaouche is a Partner with Theodorus Investment Funds where he is in charge of the Lifesciences Investments Theodorus is an early stage VC fund active in Belgium and Canada which invests mainly in university spin-offs; its historical partner being thethe Free University of Brussels (ULB) .Lotfi holds a Master in Aerospace Engineering (M.Eng.) And Business Engineering from ISAE-Supaero (France). He was previously an Engagement Manager at McKinsey & Company where he mostly served the Pharmaceuticals and Medical Devices Industry on a broad range of topics, including innovation and M&A strategy.
Pierre Detrixhe is investment manager at INVESTSUD Group. Following a Master in Bioengineering at the University of Liège and a Master in Management at the Catholic University of Louvain, he held the positions of Technology and Scientific Transfer Manager in Biotechnology. He brings more than 10 years of experience in the field of venture capital and has accompanied many companies in the start-up phase. Pierre Detrixhe also holds the position of Director at Apaxen, ATB Therapeutics, Becary, Bioxodes and Synergia Medical.
Julie Winand holds a PhD in Biochemistry and Cellular Biology carried out at the Catholic University of Louvain (Belgium). Before joining TheraVet, Julie worked at Bone Therapeutics and Novasep where she acquired experience in Product and Business Development.